of SFs they wish to receive (Appelbaum et al. 2014) . Current suggestions differentiate SFs based on their clinical validity and utility (Berg et al. 2011) , i.e. the severity of disease risks indicated, and the efficiency of available preventative methods. The American College of Medical Genetics and Genomics (ACMG) recommends (Kalia et al. 2016 ) that when clinical whole genome/exome sequencing is undertaken, the genome should be screened for pathogenic mutations in 59 genes for which preventive methods are available. This list includes single variants causing increased risk for certain types of cancer or heart diseases. ACMG recommends that if such mutations are detected, the patient should be informed about health risks that are linked to them (Kalia et al. 2016) .
Earlier research suggests that, when initially asked, majority of research participants wish to receive most types of genomic results, including those related to ancestry, pharmacogenetics, cardiovascular diseases, cancers, depression, Alzheimer's disease, Huntington's disease, and carrier status (Wynn et al. 2017a ). Most research participants state they wish to receive SFs (Jamal et al. 2017; Murphy et al. 2008 ) particularly if they are actionable-i.e. the diseases are treatable or preventable. However, actionability may mean different things to different stakeholders and cover not only availability of treatment and prevention, but also the possibility to plan one's lifestyle or reproductive choices (Mackley et al. 2016 ).
For example Jamal et al. (2017) interviewed 49 patient-participants of a clinical whole genome sequencing research study, and concluded that current classifications of the types of genomic results that are used in consent processes "may not be aligned with how individuals are conceptualizing the information they could potentially learn from WGS [whole genome sequencing]" (p. 86). The study participants perceived the distinctions between preventable/ not preventable and treatable/not treatable diseases as counterintuitive and hard to distinguish. Also, their perceptions of what constituted the most upsetting types of results varied. For example, risk for non-actionable Alzheimer's disease was not too distressing for those who had reassuring previous experience of the illness, or those who expected treatment methods to be developed in the future.
Obviously professionals and lay people approach the issue of SFs, as well as genetics in general, from different perspectives. RehmannSutter and Mahr (2016) explain that "for medical professionals, the genome is primarily a source of health information that can be used for diagnoses and disease risk assessment," whereas a lay person understands genetic information from the perspective of their personal life, identity and social relations (Rehmann-Sutter and Mahr 2016) . Hence, professional and lay perspectives on meaningful ways to categorize and report SFs related to different types of illnesses may differ to some extent (Graves et al. 2015; Jackson et al. 2012; Townsend et al. 2012) . Professionals' knowledge of various mutations and their implications provides them a different set of tools to approach the issue of SFs, compared to lay people who may instead use their experience of various types of illnesses as a background for what types of findings genome-wide sequencing might reveal.
Lay representations of different illnesses (Leventhal et al. 1980) and the extent to which they influence individuals' desire to receive SFs need to be taken into account in genetic disease categories and support decision making, lay people's views of different illnesses need to be examined and taken into account when formulating SF reporting practices. In this paper, our aim was to explore how lay people react to different types of hypothetical genomic SFs. We used four exemplar vignette letters reporting risks for Mendelian cancer syndromes or cardiovascular conditions.
| ME THODS
We conducted a qualitative vignette study that included an online writing task and focus group discussions (Barbour 2008) . We recruited Finnish adults to participate via an announcement in the Helsinki area Metro newspaper ( Fig. 1 ) (see also Vornanen et al. 2018 ).
| Procedures
An online survey was sent to 32 interested volunteers and filled in by 29 participants. The online survey contained a sociodemographic questionnaire, and a writing task accompanied by a vignette letter.
Each participant was randomly assigned to read one of four versions of the vignette letter, declaring that in their earlier hypothetical clinical whole genome sequencing a SF was identified, suggesting susceptibility to familial hypercholesterolemia (FH), long QT syndrome (LQTS), Lynch syndrome (LS), or Li-Fraumeni syndrome (LFS) (Table 1) (Vornanen et al. 2018) . Participants were asked to imagine Within a week, focus group discussions (N=23) -four focus groups with 4-7 participants -two letters were discussed in each group -duration 94-125 min, including a slide show about the two diseases themselves receiving that letter in real life, and to write down their initial reactions to it. These four diseases were chosen since the ACMG recommends reporting back mutations in genes linked to these conditions (Kalia et al. 2016) , and we had previous experience of disclosing SFs linked to LQTS (Haukkala et al. 2013 ) and of inviting LS families to attend genetic testing via letter (Aktan-Collan et al. 2007 ). To include cardiovascular diseases and cancers with varied treatment and surveillance possibilities, we chose medically treatable FH, and LFS with less efficient preventive possibilities (Schneider et al. 1993 ) compared to LS.
The vignette letters ( Table 1 ) resembled letters that were sent to research participants to reveal LQTS findings in an earlier study (Haukkala et al. 2013) and to contact untested Lynch syndrome family members to uptake genetic test (Aktan-Collan et al. 2007 ).
In those studies, the letters aimed to communicate general information about the disease, so that more detailed information could be provided in a following counseling session face to face or over the phone. We adopted a similar approach in the current study, since this kind of procedure has reasonable costs and is a likely manner of
TA B L E 1 Four vignette letters
Please read the following and write down what You would think and do in the situation
You recently visited the university hospital, where your blood sample was drawn to examine a disease, and the sample was used to sequence your whole genome (genes were spelled out letter by letter). When genes are spelled out letter by letter, it is possible that also other health related genetic mutations are found.
Before giving the blood sample, you signed a consent form stating that we can contact you if we find some other health related findings during the examination.
[ VERSION FAMILIAL HYPERCHOLESTEROLEMIA:] Your recently analyzed results indicate that you may have a hereditary disease that increases cholesterol.
The condition is called familial hypercholesterolemia, which increases blood cholesterol. Among disease carriers, cholesterol level is often over 10 mmol/l, but the value may be lower too. In Finland around 10,000 people are affected by this disease. If it is not treated, it is associated with early coronary heart disease, among men usually at the age of 40-50 years, among women approximately a decade later. The illness is dominantly inherited, which means that also some of your relatives may have the same disease, for instance your children, siblings, or parents. If one has this disease, diet alone will not affect the cholesterol level. Efficient statin medication is always needed, and often also another complementing medicine, to achievea cholesterol level that is close to normal.
We recommend you contact the laboratory of your healthcare center to make an appointment to have your cholesterol level measured. Please take this letter and the attached referral with you to the laboratory. After this, please book an appointment with internist (cardiologist) to evaluate medical and other treatment and to possibly organize further examinations in your family. Please take this letter and the referral with you also to the doctor's appointment.
[VERSION LONG QT SYNDROME:]
Your recently analyzed results indicate that you may have a hereditary susceptibility for certain types of cardiac arrhythmia.
The condition is a hereditary heart arrhythmia, so called long QT syndrome, which predisposes to certain types of arrhythmia. The susceptibility is dominantly inherited, which means that also some of your relatives may have the same susceptibility to arrhythmia, for instance your children, siblings, or parents. Most carriers of the syndrome in Finland have no symptoms. However, there are preventive methods and medical treatment for the arrhythmia. Need for treatment is evaluated individually.
We recommend you contact the laboratory of your healthcare center to confirm the diagnosis and to make an appointment for ECG ('heart film'). Please take this letter and the attached referral with you to the laboratory. After this, please book a doctor's appointment at the healthcare center or occupational healthcare, to evaluate the need for treatment and to possibly organize further examinations in your family. Please take this letter and the referral with you also to the doctor's appointment.
[VERSION LYNCH SYNDROME:]
Your recently analyzed results indicate that you may have susceptibility to a hereditary colorectal cancer syndrome.
The condition is a hereditary cancer syndrome called Lynch syndrome, which means susceptibility to e.g. early colorectal cancer, and endometrial cancers in women. The susceptibility is dominantly inherited, which means that also some of your relatives may carry the same susceptibility for cancer, for instance your children, siblings, or parents. Often there are more people with cancer in the family than usual. Colorectal cancer can be prevented through regular examinations.
We recommend that you telephone the genetics clinic of a university hospital, to confirm the diagnosis and to book an appointment for genetic counselling. During the counselling session you will receive more information on the disease, its heritability, and preventive surveillance. Please take this letter and the referral with you to the appointment.
[VERSION LI-FRAUMENI SYNDROME:]
Your recently analyzed results indicate that you may have susceptibility to a hereditary cancer syndrome.
(Continues)
reporting SFs in the Finnish context. Before use, the vignettes were tested and discussed by a student sample.
The structure of the four vignettes was parallel, but some differences were in the level of detail describing the diseases in question (see Table 1 ). When contacting people about their genetic risk via letter, the dilemma is to communicate that the risk concerns a serious health problem, but at the same time not to cause excessive distress. This is why information on the cancer syndromes and LQTS was presented at a relatively general level; no risk percentages or worst case scenarios were described. The vignette reporting FH contained somewhat more detailed information, to highlight that the finding concerns a more serious condition compared to somewhat elevated cholesterol level, which is a common problem. A brief slide show (described in next paragraph) provided participants with more information on the conditions during the focus group discussions.
Within a week after completing the writing task, participants (N = 23) attended focus group discussions led and moderated by MV and KA-C. During each session (duration 94-125, mean 114 min), two versions of the vignette letter were discussed: one revealing a cancer-related SF and the other revealing a cardiovascular-related SF (Table 2) . Each participant had read one of the two while completing the earlier writing task. The focus group guide (Appendix) included prompts on the following topics: first reactions to letter, perceptions of disease and risk, searching for information, family, recommendations for implementation, and consent. However, discussions were not strictly structured: participants spontaneously brought up their perspectives on these topics, and they were encouraged to discuss the topic of SFs and different diseases freely.
In the midst of the discussion, KA-C provided a brief slide show (13 slides) about the two diseases under discussion, and answered participants' questions. KA-C is a psychotherapist and a medical doctor, who has been working as a physician, specializing in clinical genetics. She has several years of experience in counseling and providing genetic information to people. She provided the study participants with the type of information about the different diseases that they would receive in a brief genetic counseling session.
The slide show contained more detailed information on the diseases:
mode of inheritance, prevalence, magnitude of risk, typical age of onset, symptoms, and preventive methods. Participants were informed about special features related to the syndromes e.g. high penetrance, early age of onset, multiple tumors occurring among those affected, and childhood manifestations.
| Data Analysis
Written reactions to receiving the letter and transcribed focus group discussions were analyzed using inductive thematic analysis (Braun and Clarke 2006) to answer the following question: In which ways does type of disease matter when receiving genetic SFs? In our earlier study (Vornanen et al. 2018) , we reported the focus groups' perspectives on receiving SFs in general. For the current analysis, we included the written accounts and those parts of the focus group discussions, which concerned particular diseases and their meanings. MV coded the data and grouped codes into larger 
TA B L E 2 Diseases discussed in four focus groups

Please read the following and write down what You would think and do in the situation
The syndrome is called Li-Fraumeni syndrome, which is a rare syndrome causing susceptibility to several cancers. The susceptibility is dominantly inherited, which means that also some of your relatives may carry the same susceptibility for cancer, for instance your children, siblings, or parents. The cancers typically occur at a relatively young age and they may sometimes recur. Tumors associated with Li-Fraumeni syndrome include, among others, soft tissue sarcoma, breast cancer, and brain tumor.
We recommend that you telephone the genetics clinic of a university hospital to book an appointment for genetic counselling. During the counselling session you will receive more information on the disease, its heritability, and preventive surveillance and treatment. Please take this letter and the referral with you to the appointment.
[
COMMON TO FOUR VERSIONS:]
If you have any questions, you can contact the healthcare personnel below.
[Hypothetical contact details for personnel at the university hospital]
Please imagine this situation and write down what You would think and do in this situation.
(Open responses)
We ask you to imagine being in the situation described in the letter until you come to the focus group discussion, and to think about how you would react to the letter.
themes (Braun and Clarke 2006) ; KA-C agreed with the interpretation. Overall thematic structure was further elaborated and agreed by MV, KA-C, and NH. To ensure anonymity of the written accounts, we will not link individual participants' written accounts (referred by participant numbers P1-P29) with their comments in focus groups (A-D, A1 refers to the first speaker of focus group A).
| RE SULTS
Participants were primarily female, middle-aged (between 20 and 64 years, mean 49), and with diverse educational backgrounds ( Table 3) .
The sample was diverse in professions, including e.g. entrepreneur,
teacher, artist, salesperson, welder, accountant, and archeologist.
Three participants reported working in healthcare professions (nurses, personal assistant). Reasons for not participating focus groups after completing the writing task (N = 6) were not systematically collected, but included difficulties to find a baby sitter and being ill at the time of the focus group discussion. The average age of these six participants was 44 years (range 30-61).
Perspectives on receiving SFs tended to vary according to different diseases. Vignette letters (Table 1) reporting genetic risk for cancer were perceived as more threatening compared with letters reporting risks for cardiovascular conditions. Earlier experiences and understandings of the disease described in the letter could either amplify or alleviate emotional reactions to it.
| First Reactions in Written Accounts: Interplay of Familiarity and Perceived Severity
Individuals' descriptions of their first reactions to receiving the hypothetical letter about SFs varied from neutral or grateful to terrified, angry, or regretting giving consent to receive this information.
Individual's familiarity with the disease described in the letter together with perceptions of its severity and treatability, shaped their initial reactions to receiving information about SFs. In their written accounts (2-333 words, 1-26 sentences), each participant commented on only one disease (FH, LQTS, LS or LFS) that had been described in the hypothetical letter they received. Some differences between the reactions to the four diseases were identified.
| Familial Hypercholesterolemia
First reactions to receiving the FH letter were the most neutral.
Participants described being calm or slightly worried, and commented that they would contact health care personnel for further examinations, as suggested in the letter: "I would act according to the recommendations in the letter" (P20). One participant (P17) briefly described being "disappointed" on learning that leading a healthy lifestyle was not enough to prevent hypercholesterolemia.
Written reactions to FH tended to be short, including the very briefest one containing only two Finnish words: "I would go for laboratory examinations" (P21). 
| Long QT Syndrome
| Lynch Syndrome
First reactions to the LS letter were twofold. Initial shock was processed through focusing on the preventive methods mentioned in the letter: "Sure the information would be overwhelming for a moment (-) I would find out about the treatment/ prevention possibilities as much as I can and start trying those" (P1). Coincidentally, one of the participants who had received the LS letter had a family history of colorectal cancer. Her written reaction highlights the fact that preventive measures mentioned in the letter may pale into insignificance in the light of one's personal experiences: "I'm terrified (-) I will call the hospital immediately for further instructions (-) I don't want the same destiny (-) I would die slowly too" (P4). Three out of the four focus groups spontaneously commented that receiving genetic risk information about psychiatric illnesses (e.g., bipolar disorder, schizophrenia), incurable neurological disorders (e.g., Alzheimer's disease), alcoholism, or intellectual disability of children would be more distressing than receiving SFs about somatic diseases.
TA B L E 3 Descriptive characteristics of study participants who completed a writing task
Most participants made no straightforward statements that they either would or would not like to know risks that they found hardest to come to terms with. However, they outlined several reasons why they found risk information on common somatic diseases less threatening than other types of disease risks. Psychiatric and somatic diseases were, in general, perceived to differ in their (1) severity in terms of lived experience of disease, (2) treatability and access to treatment,
level of stigma, and (4) individual's responsibility for managing the risk. Participants acknowledged that medication and treatment exist for psychiatric disorders, too. As the above quote indicates, however, the effectiveness of treatment for psychiatric disorders tended to be evaluated as less predictable. In addition, participants commented that these treatments were more difficult to access: A7: if I have a (pause) some kind of physical illness, they won't tell me that "Well let's wait until you rot, then we will take you in for treatment" but they will start to examine [A2: Yeah] based on first symptoms
| Severity in Terms of Lived Experience and Access to Treatment
to find out what it could be and as soon as possible start medication and treatment so that it will not get worse [A2: It's about attitudes] but for psychiatric illnesses it's completely the other way around
In addition to lived experience of disease and access to treatment, the burden of knowing one's risk for disease was linked to potential stigma associated with having the disease and responsibility for managing disease risk. These were seen to vary across different diseases.
| Stigma and Perceived Responsibility to Manage Risk Vary Across Diseases
Participants perceived psychiatric disorders as more stigmatizing compared to somatic diseases: "stigma is thrown upon the whole family [when psychiatric disorder occurs]" (A2). However, also rare somatic diseases were seen to have the potential to isolate individuals and families, since peer support and treatment could be harder to find. Thus, as a consequence of the "visibility" of psychiatric symptoms or preconditions and difficulties to access treatment, individuals were seen as more responsible for preventing and coping with psychiatric illnesses compared to somatic illnesses.
B1: when you know there is a hereditary risk for depression in your family (-) then you can start to, build your life or your lifestyle, take it into account, like for example "I have to avoid extreme stress, because stress predisposes to depression" (-) or hereditary susceptibility to alcoholism, also then, when the person knows it, they can influence, so that it is perhaps best to stay away from using alcohol completely
In contrast, knowledge of genetic risk for hypercholesterolemia had the potential to alleviate the individual's responsibility to prevent it by healthy lifestyle. One participant described how it would be a relief to find out a genetic susceptibility after failing to lower cholesterol as a result of dietary changes. 
| D ISCUSS I ON
The current study aimed to examine whether lay perspectives on re- In focus group discussions, participants also considered cardiovascular diseases and cancers similar in many ways; they lumped them into the category of common, familiar somatic diseases. Receiving genetic risk information on common somatic diseases was, in general, perceived less threatening than potentially receiving genetic risk information related to other types of diseases; psychiatric diseases like schizophrenia, alcoholism, or Alzheimer 's disease. Comparing views about somatic and psychiatric genetic risks was not part of the original study plan, but participants spontaneously emphasized this comparison during three out of four focus group discussions.
Our study participants made sense of potential SFs through their personal experiences of different diseases. Preventive methods mentioned in the vignette letters provided little reassurance in comparison to negative personal experiences of (similar) illnesses. Earlier experiences influenced these perspectives even after receiving more specific information on preventative methods related to the four exemplar diseases during the focus group slide show. In line with previous literature (Shiloh 2006; van Oostrom et al. 2007 ), our results suggest that lay illness representations (Leventhal et al. 1980 ) of different diseases need to be taken into account when disclosing SFs. Since various diseases linked to SFs may either be familiar or unfamiliar to the recipient, personal experiences are likely to play a central role (Jamal et al. 2017; Wynn et al. 2017b ). Since individual experiences vary greatly, predicting reactions to different types of SFs seems challenging.
Cancer was, in general, perceived as more threatening than cardiovascular diseases. Participants tended to intuitively process risk for cancer in quite general terms, even though they explicitly pointed out that types of cancers vary. Hence, evaluations of risks for LS and LFS differed to a lesser extent than professionals might expect, due to LFS's earlier onset and less efficient preventive possibilities (Schneider et al. 1993 ). However, none of the focus groups discussed these two cancer syndromes together; had this been the case these differences might have been more evident.
Similarly, none of the focus groups discussed LQTS and FH at the same time, but FH seemed a great deal more familiar compared to LQTS. Participants easily understood that FH concerns high cholesterol, which they knew to be a common problem and a risk factor for heart disease. Hence, the FH letter was perceived not very frightening, but useful and easy to understand. In contrast, it was harder for participants to make sense of what LQTS means for one's life, which led some participants to express considerably more worry than others. Despite these differences, we emphasize that no simplistic conclusions should be drawn; FH may not be less threatening to everyone, and reactions are likely to depend on varied past experiences of (similar) conditions.
| Distinguishing Mendelian and Polygenic Risks
When conducting genome-wide sequencing, it is possible to detect high risk single variants, but also to calculate polygenic risk scores for multifactorial diseases. So far, polygenic risk scores are not widely used in healthcare settings, but private companies offer direct-to-consumer testing for susceptibilities of varied multifactorial diseases (Bunnik et al. 2012 ).
Professionals may approach genomic results from the point of view of known variants and their implications. In contrast, lay people tend to approach genomic risk information primarily from the point of view of disease type, instead of the magnitude of risk or mode of inheritance (Bacon et al. 2015) . Our study participants made sense of hypothetical SFs-related to Mendelian cancers and cardiovascular conditions-through their general understanding of cancer and heart disease. This suggests that communicating different implications of Mendelian and polygenic risks requires special care. This may be particularly important with disease types that can be either Mendelian or multifactorial (e.g. cancer and Alzheimer's disease).
However, comparing perspectives on Mendelian and polygenic risks was not the original aim of our study, hence, further research in this area is needed.
| Contrasting Somatic and Psychiatric Risks
Unprompted, our study participants stated that they were more hesitant to receive genetic risk information for psychiatric disorders compared to actionable somatic diseases, in line with previous literature (Bacon et al. 2015; Bunnik et al. 2012) . In an earlier Finnish survey from the 1990s, physicians and midwives were less in favor of genetic screening for schizophrenia compared to somatic diseases like cancer or FH (Toiviainen et al. 2003) . Results of the current study support Bunnik et al.'s (Bunnik et al. 2012) concerns that psychiatric genomic results could potentially stigmatize, threaten personal integrity or evoke a self-fulfilling prophecy. Importantly, however, the reasons why our study participants considered psychiatric genomic results threatening were not primarily based on a fixed, essentialist distinction between psychiatric and somatic diseases. Severity of lived experience, access to efficient treatment, and level of stigma were considered to vary across diseases in general.
| Not Only Treatability, but Also Access to Treatment
In addition to whether treatment exists, our participants discussed whether treatment is accessible for all types of diseases. Even though tax-funded public healthcare is available in Finland, the current healthcare system includes many pitfalls and does not always function in an optimal manner. The perception that early psychiatric care is not easily available amplified participants' concerns around potentially receiving psychiatric genomic risks. On the one hand, the possibility to monitor and manage early psychiatric symptoms could increase feelings of control over the risk. On the other, without early access to treatment if needed, the same possibility might become a burdensome responsibility for the individual to cope with psychiatric symptoms on their own.
Shiloh (2006) 
| Genetic Risk May Stigmatize or Provide Relief
Finally, our results suggest that individual reactions to different types of SFs may depend on whether the SFs predict future illness or explain current symptoms. Our results suggest that those who, for instance, struggle with high cholesterol may regard genetic susceptibility to be a relief from responsibility and guilt over failing to decrease cholesterol by healthy diet. In contrast, risk for future illness, particularly psychiatric disorders, was seen to potentially stigmatize the whole family. Similarly, previous research has found that knowledge of genetic risk for obesity may be a relief for those with weight problems, but induce negative affect in those with normal weight (Meisel et al. 2012) . Also among those who struggle with addictive problems (Dingel et al. 2017 ) and among families with psychiatric disorders (Austin and Honer 2005) genetic explanations may reduce experience of stigma.
Hence, it seems that genetic risk information has different meanings for those who already suffer from the condition to some degree-providing explanation and relief-compared to nonsymptomatic individuals who might, in contrast, experience the information as stigmatizing.
| Study Limitations
Our study has a number of strengths and limitations. First, the participants were self-selected and primarily middle-aged females; however, their educational and professional background was diverse. As the sample was not drawn from genetic patients or genetic research participants, the results provide some insight into perspectives of those who have limited prior experience of genetic testing. Second, it must be noted that hypothetical accounts do not always match with real situations; for example people tend to be more in favor of receiving all possible types of SFs in a hypothetical situation compared to a real situation after pre-test genetic counseling (Wynn et al. 2017a ). However, a strength of this design was that we were able to collect participants' immediate accounts on the hypothetical findings.
Our focus group participants provided various ideas on how the vignette letters could be improved. Some participants said the letters were perfectly considerate and informative, while others found sending such risk information via letter unacceptable, or stated that the letters were not comprehensible for everyone. Some wished for more information, others thought the level of detail was just right.
Further studies need to test different types of letters to find the best practical solutions.
Choosing to discuss one cancer syndrome and one cardiovascular syndrome in each session possibly encouraged comparisons between these disease categories, whereas asking participants to discuss, for example, two cancer syndromes in one session might reveal more nuanced evaluations of different types of cancer syndromes. However, focus group discussions provided insight into why SFs for certain diseases might be regarded as more distressing than others. Since we allowed participants to elaborate varied points of views on the topic, we identified a wide range of perspectives that were meaningful for participants, some of which we had not initially expected. Bearing this in mind, our results should be interpreted as exploratory and descriptive: further experimental and quantitative research is needed to draw conclusions on generalizability of differences in reactions to different diseases.
| CON CLUS IONS
In addition to clinical severity and actionability of different diseases, lay illness representations may shape reactions to, and coping with, We argue that lay illness representations need to be taken into account, if we want to find the best ways of categorizing and reporting SFs.
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APPENDIX
Topic guide for focus groups
We (MV & KA-C) welcome all participants and introduce ourselves.
We tell the participants that they need not tell their names, and the interview is recorded and transcribed so that the researchers can analyze the conversation. We remind them that participants' names will not be linked to citations. All citations will be made so that anonymity is secured. The transcribed data will be stored behind locked doors.
Participants are told they no longer need to imagine themselves as the recipient of the letter. They can comment it from whichever position they like.
We tell them that each participant read a letter, but under the present discussion there are two versions of it, i.e. risk information on two different diseases. In the present group, the participants have received letters concerning diseases x and y (see table below), and we will go through them together. How would you like to know about the finding?
Have your thoughts changed after the first reaction?
D I S E A S E A N D U N D E R S TA N D I N G O F S US CE P TI B I LIT Y
• At some point of the discussion, the participants are told more about the two diseases (slide show), and also other diseases if necessary. When need for this knowledge arises, the participants are asked to first describe what they have learned about the diseases so far. After this, they are told what is known about the diseases in the medical field. This is why delivering knowledge on the diseases is not strictly fixed to any particular phase of the interview.
What did the disease seem like?
Could someone interpret the letter to mean that they already have the disease instead of only susceptibility?
How do you define susceptibility and illness?
Based on the letter, what kind of disease is this? How likely is it?
S E A RCH FO R K N OWLE D G E
Did you try to find out information on the disease after the letter?
If you did, where did you find information? What did you find out?
What did you try to find out?
Did the disease seem different after searching information, how?
FA M I LY A N D H E R ITA B I LIT Y
At which point did the letter raise thoughts about family?
What kind of thoughts and questions arose concerning family?
Do you have previous experience on heritable diseases? Why did you choose to participate this study?
R ECO M M E N DATI O N S FO R PR AC TI C A L I M PLI C ATI O N
What kind of diseases or susceptibilities would you like to be informed of in the future?
How should this information be delivered?
CO N S E NT TO R ECE I V I N G I N FO R M ATI O N
If you imagine having consented to receiving information on genetic susceptibilities during a medical appointment, would you like to decline this sort of information after receiving this letter?
In practice, how should consent be obtained, when dealing with issues like this?
(We may tell them how consent is obtained, for instance, in the Finnish biobank research register.)
